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Abstract Adouble-blind, randomized crossover study in 28 asthmatic patients assessed the relative therapeutic in-
dex for inhaled formoterol and salbutamol. Pre-drug administration FEV1 (mean 2.08 l) was 49--93% of predicted and
reversibility16--82% after inhalation of salbutamol.Patients inhaled single doses of formoterol (Oxiss) (4.5,18 and 54 mg,
delivered doses) viaTurbuhaler, salbutamol (Ventolins) (200 and1800 mg) via pressurizedmetered dose inhaler (pMDI)
and placebo at intervals of 48 h or more. Individual maximum FEV1 and minimum S-K
+ were calculated.Relative local
(maximum FEV1) and systemic (minimum S-K
+) dose potencies, and their ratio, the relative therapeutic index, were
estimatedusinga non-linearmixed effectmodel.The drug effectswerewell tolerated and dose dependent.A log-linear
approximationwas used to describe the bronchodilatory effect, whereas a sigmoid approximationwasmore aptto de-
scribe the decrease in serumpotassiumconcentration. Abivariate dose--responsemodelbased onthese principleswas
fitted simultaneously to alldata.Themeanrelativetherapeutic indexbetween formoterol 4.5--54 mg givenviaTurbuhaler
and salbutamol 200--1800 mg givenvia pMDIwas estimated to be 2.5 in favour of formoterol; this trendwas not statisti-
cally significant.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2002.1291, available online athttp://www.idealibrary.comon
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b2-receptor agonists, such as salbutamol and formoter-
ol, are widely used for bronchodilation in the
treatment of asthmatic patients. Inhaled, they are e¡ec-
tive bronchodilators with fast onset of action and amini-
mum of systemic adverse reactions (1). Formoterol
fumarate dihydrate (hereafter ‘‘formoterol’’) is a fast-
and long-acting b2-agonist when delivered by the
pulmonary route (2,3). Two strengths of formoterol
(Oxiss) are available for administration via the dry
powder inhaler Turbuhaler, 4.5 and 9mg per inhalation
(on some markets denoted as metered doses of 6 and
12mg per inhalation), and two strengths of salbutamol,
100 and 200mg per inhalation are normally available for
administration via the pressurizedmetered dose inhaler
(pMDI).
b2-agonists mediate uptake of potassium into skeletal
muscle leading to the concentration of serumpotassiumCorrespondence should be addressed to: Johan Rosenberg,
Experimental Medicine, AstraZeneca R &DLund, Sweden, SE-22187
Lund, Sweden.Fax: +46 [46] 33 7191;
E-mail: Johan.Rosenborg@astrazeneca.combeing suppressed (4). The e¡ect on serum potassium
declines during repeated administration of b2-agonists
(5,6). A higher dose of b2-agonist is required to detect
serum potassium suppression than to detect bronchodi-
lation. Thus, the serum concentration of potassium is
negligibly a¡ected after inhalation of salbutamol at
doses below 500mg (7). The single-dose e¡ect of
inhaled formoterolon serumpotassiumis negligible after
4.5mg administered via Turbuhaler (data on ¢le, Astra-
Zeneca).
The therapeutic index of a drug, de¢ned as the ratio
between potencies of desired and undesired e¡ects, can
serve as an indication of the therapeutic window or as a
measure of the overall usefulness. Judged from serum
potassium suppression, a marker for undesired systemic
e¡ects of b2-agonists, formoterol is about 60 times as
potent as salbutamol (8). Simultaneous re-estimations
of thismeasure of relative systemic dosepotency and re-
lative dose potency for the desired bronchodilating ef-
fect for inhaled formoterol and salbutamol, respectively,
weremade.The objectivewas to assess a relative thera-
peutic index, de¢ned as the ratio between relative
bronchodilating potency and relative serum potassium
suppressing potency of these drugs.
De¢nitions, symbols, and calculations of individual
parameters
Baseline Measurementmade in themorning before
administration of randomized
study treatment.
F4.5,F18,F54 Formoterol 4.5,18, and 54 mg
inhaledviaTurbuhaler.
FEV1 Forced expiratory volume in1s (l)
Placebo Randomized and double-blind
control treatment.
Pulse Measurement via radial artery
(bpm, beats/min).
Q--Tc Heart rate corrected Q--T interval,
Q T
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
heart rate
60
q
(ms).
S200,S1800 Salbutamol 200 and1800 mg inhaledvia pMDI.
S--K+ Serumconcentration ofthe potassiumion
(mmol/l).
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PATIENTS STUDIED
The study was performed in accordance with the De-
claration of Helsinki and approved by the local Ethics
Committees in Eger, Budapest, Nogra¤ dga¤ rdony, Pe¤ cs,
and Gy˛r, Hungary. Before enrolment, asthmatic pa-
tients gave their informed consent after receiving oral
andwritten information.
Study patients
Asthmatic patients were recruited provided they had a
normal serum potassium concentration and no history of
clinically relevant heart disease, ECG abnormality or hy-
pertension. Eligibility was based on a physical examina-
tion, vital signs and standard clinical laboratory tests.
Asthma was diagnosed according to the AmericanThor-
acic Society guidelines (9). Patients were included only if
they could show a stepwise dose--response to salbutamol
inhaled via pMDI in the range 100--200 or 100--400mg,
overall by at least 15%. Baseline FEV1was not to vary by
more than712% between the enrolment visit and study
days. Furthermore, baseline FEV1was not to increase by
more than15% from one study day to the next.
Twenty-nine patients were randomized to six treat-
ment periods.One patient, who discontinued the study
after one treatment because baseline criteria for FEV1
were not ful¢lled, was excluded from the statistical ana-
lysis.
The 28 asthmatic patients who completed the study
were all Caucasian non-smokers (three ex-smokers).
Their mean age was 43 (range 20--64) years and mean
weight 72 (range 49--91) kg.Mean baseline FEV1was 2.08
(range 1.46--2.90) l or 69 (range 49--93)% of predicted
normal value.The reversibility after inhalation of salbuta-
mol was16--82%. All patients showed at least 50% addi-
tional reversibility after a cumulative dose of 200 or
400mg salbutamol compared with a single dose of
100mg.Two asthmatic patients completed the study and
were included in the evaluation although they were not
fully eligibleFone had angina pectoris and one had un-
speci¢ed hypertension. Twenty-four of the 28 patients
were on asthma medication: 18 on bronchodilators, and
18 on corticosteroids (notnecessarily the samepatients).
Protocol
The study was designed to show dose--response for for-
moterol both with respect to bronchodilation and ser-
um potassium suppression. Therefore, patients were
allocated to inhale three single doses of formoterol fu-
marate dihydrate (Oxis) (4.5,18 and 54mg) viaTurbuhaler,
two single doses of salbutamol (Ventolins) (200 and
1800mg) via pMDI, and placebo in a double-blind, rando-
mized and crossover fashion at intervals of 48h ormore.All active treatments were expected to have a broncho-
dilatinge¡ect, and at least18 and 54mgof formoterol and
1800mg of salbutamol were expected to be serum po-
tassium suppressive. Inspiratory £ow viaTurbuhaler and
pMDI was monitored by use of a modi¢ed Vitalographs
MDI-Compact spirometer (10). Strenuous activity andin-
take ofbeverages containing ca¡eine or alcoholwerenot
allowed before and during study days. A light breakfast
was served before and a light lunch at 4h after drug ad-
ministration on studydays.Water was allowedadlibitum.
Salbutamol100mg was to be inhaled regularly at least
twice daily via pMDI for 10 days before the ¢rst treat-
ment. Thereby, a clinically relevant degree of tolerance
to the tested drugs was to be ensured. Other regular
treatments were kept constant during the study.
FEV1 and serum potassium were assessed before
(15min) and at 0.5,1,1.5, 2, 3 and 4h after drug adminis-
tration.FEV1wasmeasured, with the patient sitting in an
upright position, using a Vitalograph Alpha spirometer
(Vitalograph Ltd., U.K.) according to standards de¢ned
by the AmericanThoracic Society (11).Venous bloodwas
drawn via an indwelling catheter into tubes without an-
ticoagulant, with the patient supine or sitting reclined.
After blood coagulation, serumwas prepared by centri-
fugation at1400g and then stored at 201C. An ion-se-
lective electrode was used to measure the serum
concentration of potassium.
Pulse and blood pressures were checked at 15min,
and 0.5, 1, 1.5, 2, 3, 4 and 8h using standard methods.Q-
Tc (heartrate correctedQ--T interval), obtained from12-
lead electrocardiograms, was recorded at 15min and
8h. Information regarding adverse events was collected
by means of a standard question: ‘‘Have you had any
health problems since your last visit or since you were
last asked?’’.
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FIG. 1. Mean FEV1 values at scheduled assessment times after
placebo, formoterol (F) 4.5, 18 and 54 mg, and salbutamol (S)
200 and1800 mg.
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FIG. 2. Mean serum potassium concentrations at scheduled
assessmenttimes after placebo, formoterol (F) 4.5,18 and 54 mg,
and salbutamol 200 and1800 mg (S).
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Analysis ofmaximum orminimumvalues
Analysis of variance models with patient, period, and
treatment as factors andbaseline as covariatewereused
for the maxima of FEV1, pulse and systolic blood pres-
sure, and for theminima of serumpotassium concentra-
tion and diastolic blood pressure. Missing individual
baseline values for serum potassium concentrations
were replaced by the within-patient mean baseline for
the other treatments. A multiplicative model was used
for FEV1.Treatmentmeans were compared pairwise.
Estimation ofthe relative therapeutic index for formoterol
and salbutamol
A bivariate non-linear mixed-e¡ect model was used to
estimate the relative dose potencies and the relative
therapeutic index based on minimum serum potassium
andmaximum FEV1 (Appendix A).
The ¢tted model is presented graphically superim-
posed on the adjusted mean maximum increase in FEV1
andminimum serumpotassiumconcentrationvalues ob-
tained from the analyses of variance (cf. above).
RESULTS
All treatments were well tolerated. No speci¢c adverse
event pattern was discernible. ECGs were normal; sinus
rhythm was always seen. Two patients had extrasystoles
at the check 8h afterdosing thatwerenotpresent before
dosing (in onepatient after F4.5 and S200, andin the other
after S1800).Normal ECGswere recorded from these pa-
tients at subsequent visits. Some patients did not inhale
salbutamol regularly as prescribed by the protocol.
Description of data and analysis of
maximume¡ects
Mean baseline FEV1 and S--K
+ on study days was 2.09--
2.14 l and 4.27--4.34mmol/l, respectively.
Bronchodilationwas seen after inhalation of formoter-
ol and salbutamol (mean FEV1 at scheduled assessment
times are shown in Fig.1).Themaximum FEV1, seemingly
reached within 4h after dosing, was statistically signi¢-
cantly greater after the active treatments compared
with placebo: 13, 17, and 20% after F4.5, F18 and F54, re-
spectively, and 7 and 15% after S200 and S1800, respec-
tively. Statistically signi¢cantly greater maxima were
seen after F54 compared with F4.5 (6.5%) and after
S1800 compared with S200 (7.5%), showing that bronch-
odilation was dose dependent within the studied range
for both drugs.Themaxima after all doses of formoterol
were statistically signi¢cantly greater than S200 and so
was themaximum after F54 comparedwith S1800.The serum potassium concentration was suppressed
by both formoterol and salbutamol (mean concentra-
tions at scheduled assessment times are given in Fig. 2).
The minimum concentration, seemingly reached within
4h, was statistically signi¢cantly lower than placebo
after formoterol 18mg (0.29mmol/l) and 54mg
(0.61mmol/l), and salbutamol 1800mg (0.30mmol/l),
but not after formoterol 4.5mg (0.04mmol/l) or salbu-
tamol 200mg (0.07mmol/l). More individual values
below the reference range of serum potassium
(3.5--5.0mmol/l) and statistically signi¢cantly lower
minima were seen after F54 compared with F18
FIG. 3. Mean maximum FEV1 and minimum serum potassium
concentration together with approximations of the dose--re-
sponse relationships. Dashed lines indicate the dose of salbuta-
mol that is equipotent to formoterol 9 mg.The solid line, parallel
to the x-axis, indicates the 95% con¢dence interval for the esti-
mate.Note that relative increase inmaximum FEV1compared to
placebo rather than di¡erences are plotted aganist dose. The
reason is that log transformed data were used in the statistical
analysis.
RELATIVE THERAPEUTIC INDEXOFFORMOTEROL 415(0.32mmol/l) and after S1800 compared with S200
(0.23mmol/l), showing that serum potassium suppres-
sionwas dose dependentwithin the studied range.
The mean baseline values for cardiovascular variables
were 71--75 bpm (pulse), 126--132mm Hg (systolic blood
pressure), 79--82mm Hg (diastolic blood pressure), and
384--394ms (Q--Tc). Maximum e¡ects seemed to be
reached within 4h after dosing (not shown). The maxi-
mumpulsewas statistically signi¢cantlygreater thanpla-
cebo after F54 (+10bpm) and S1800 (+8bpm) but not
after the other treatments.The systolic blood pressure
did not increase, but rather unexpectedly seemed to de-
crease during the ¢rst 4h after dosing (not shown).The
minimumdiastolic bloodpressurewas statistically signif-
icantly lower than placebo after salbutamol 1800mg
(--4.9mm Hg) but not after the other treatments. The
mean Q--Tc at 8 h was statistically signi¢cantly longer
than placebo after F54 (+17.5ms) but not after the other
treatments.
Estimation of the relative therapeutic index
for formoterol and salbutamol
A log-linear approximation was used to describe the
bronchodilatory e¡ect, whereas a sigmoid approxima-
tionwasmore apt to describe the decrease in serumpo-
tassium concentration. The ¢tted model superimposed
onmeanmaximum FEV1values andminimum serum po-
tassium concentrations obtained from the analyses of
variance are shown in Fig. 3. The model provided good
approximations of the means and could therefore be
used to estimate relative dose potencies and the relative
therapeutic index.The estimatedrelative dose potencies
are indicated in the model as the dose of salbutamol in-
haledvia pMDI corresponding to formoterol 9mg inhaled
viaTurbuhaler.Formoterol was estimated to be 88 times
as potent as salbutamol with regard to suppression of
serum potassium and 215 times as potent regarding in-
crease in FEV1.The relative therapeutic index was there-
fore estimated to be 2.5 (95% con¢dence interval: 0.9--
6.5) in favour of formoterol. The con¢dence limits for
the relative therapeutic index included 1, so the di¡er-
ence between the two drugs was not statistically signi¢-
cant.
DISCUSSION
Arelative therapeutic indexbetween formoterol inhaled
viaTurbuhaler and salbutamol inhaled via pMDI was de-
¢ned and estimated, to the best of our knowledge, for
the ¢rst time in asthmatic patients.The estimate, based
on the simultaneous assessments of ratios between rela-
tive bronchodilating and serum potassium suppressing
potencies between the two drugs, favoured formoterol.Dose potency
Studies addressing the dose potency of b2-agonists often
fail to show dose bronchodilating response because in-
adequate dose spans render detection of treatment dif-
ferences di⁄cult. In the present study, however, clear
416 RESPIRATORYMEDICINEdose--responsewas seenwith respect to bothmaximum
bronchodilation and serumpotassium suppression.
Themeanmaximum FEV1after delivered doses of for-
moterol 4.5 and18mg (equivalent to metered doses of 6
and 24mg via Turbuhaler) were 113 and 117% of placebo,
respectively, which corroborated previous results (3).
Maximum bronchodilation of salbutamol was moderate
comparedwith placebo, but the net increase from base-
line, about 0.5 l (7%) after 200mg and 0.7 l (15%) after
1800mg, was similar to that seen previously after such
doses of salbutamol inhaled cumulatively via pMDI
(12,13).Unexpectedly, therewas a potential for broncho-
dilating improvement for doses of formoterolup to 54mg
and salbutamol up to1800mg.
In vitro estimates suggest that the bronchodilating po-
tency of formoterol may be100--200 times greater than
that of salbutamol on a molar basis (14,15), i.e. about
60--120 times greater on aweightbasis.The relative local
potency in this study with respect to bronchodilation
was on average 215 on a mg for mg basis in favour of for-
moterol, giving fair clinical support for the in vitro data.
The lower relative serum potassium suppressing po-
tency essentially con¢rmed previous in vivo estimates in
healthy subjects and asthmatics (8). Recently, caution
was called for because inhaled formoterol and salmeter-
olmay have narrow therapeutic windows (16).However,
this study indicated that inhaled formoterol may be a
therapeutic improvement, at least, comparedwith areli-
able short-acting b2-adrenoceptor agonist analogue.
The bronchodilating e¡ect of salbutamol could have
been blunted by additives in the pMDIs (17). However,
even if this were the case in the present study, it would
not have confounded the estimate of relative bronchodi-
lating potency between formoterol Turbuhaler and sal-
butamol pMDI, since patients inhaled via pMDI
(salbutamol or placebo) on all study days in order to
maintain the double-blind nature of the study.
Patients should have inhaled salbutamol regularly dur-
ing a 10-day run-in, but that was not always the case.
Therefore, the degree of tolerance to b2-agonists might
have varied between patients. However, the relative
systemic potency between formoterol and salbutamol
seems to be una¡ected by the degree of tolerance
induced by regular treatment with a b2-agonist (8) and
there is no reason to believe thatrelative local bronchodi-
lating potency would be a¡ected di¡erently. Therefore,
the deviations from the prescribed run-in should not have
in£uenced the estimate of the relative therapeutic index.
Relative therapeutic index
This study indicated that the serum potassium suppres-
sion caused by inhaled formoterol is less pronounced
than the suppression caused by an equie¡ective bronch-
odilating dose of inhaled salbutamol.Formoterol and sal-butamol are both b2-selective agonists and there is no
obvious reason why they should behave di¡erently at
the receptor level in di¡erent organs.
Drugs aimed at exerting their e¡ect in the airways are
more selective after inhalation than after oral adminis-
tration.This pharmacodynamic selectivity is further im-
proved if the inhaled drug is somehow retained in the
airways (18,19). Distribution into the lipid part of cell
membranes is thermodynamically more favourable for a
lipophilic b2-agonist such as formoterol than for a hydro-
philic one such as salbutamol (20). Slow distribution of
airway-retained formoterol from the lungs to the sys-
temic circulationhelps tomaintain a therapeutically rele-
vant concentration of formoterol at the site of action in
the lungs, and so prolongs bronchodilation. However, it
has been shown that systemic concentration of inhaled
formoterol is too low, even after relatively high doses,
to prolong the systemic e¡ects to a similar extent as
seen with an equie¡ective dose of salbutamol (8). This
study indicated that the two drugs also may di¡er with
respect to the relation between local and systemmagni-
tudes of e¡ect.Thus, a more pronounced di¡erence be-
tween local and systemic exposure of inhaled formoterol
compared with inhaled salbutamol may explain not only
thewell-known di¡erence in duration of bronchodilation
but also why the therapeutic index would be more fa-
vourable for formoterol.
CONCLUSION
Formoterol (Oxis) Turbuhaler may have a more favour-
able ratio between local and systemic potency than sal-
butamol pMDI. The clinical implication would be that
systemically mediated side-e¡ects of inhaled formoterol
may be less pronounced than with an equie¡ective
bronchodilating dose of inhaled salbutamol.
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APPENDIXA
A parametric model was ¢tted to data in order to esti-
mate the relative therapeutic index between formoterol
and salbutamol.The dose--response curves for formoter-
ol and salbutamolwere assumed to be parallel. Individual
minimum S--K+ and Fin accordance with the basic
RELATIVE THERAPEUTIC INDEXOFFORMOTEROL 417assumption of multiplicity for the relative increase in
FEV1FI log (Maximum FEV1) for all doses were analyzed
simultaneously as functions of the logarithms of formo-
terol and salbutamoldoses.Theparameters of themodel
(Models1) were assumed to be normally distributed ran-
dom variables within the group of investigated patients
and thewithin-patient variationwas assumed to be inde-
pendent for S-K+ and FEV1.Themodelwas ¢tted to data
using the Vonesh--Carter method (21). Period e¡ects
were adjusted for, using a ¢xede¡ectmodel, andbaseline
di¡erences were adjusted for using baseline as covariate
for the placebo e¡ect.
MinimumS-Kþ ¼
a1; placebo
a1 1 11þeðb1 ðc1logðDoseÞÞ
 
; formoterol
a1 1 11þeðb1 ðd1logðDoseÞÞ
 
; salbutamol
8><
>:
logðMinimum FEV1Þ ¼
a2; placebo
a2 þ b2ðlogðDoseÞ þ c2Þ; formoterol
a2 þ b2ðlogðDoseÞ þ d2Þ; salbutamol
8<
:
The relative dose potency was estimated as eðc1d1Þ
for S-K+ and as eðd2c2Þ for FEV1.The relative therapeutic
index was estimated as eððd2c2Þðc1d1ÞÞ. Con¢dence in-
tervals for the estimates were calculated using the
asymptotic normality of the estimates.
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